6615.Two
6615.TWO operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research to develop and commercialize innovative healthcare solutions.
Business. 6615.TWO operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research to develop and commercialize innovative healthcare solutions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6615.TWO operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research to develop and commercialize innovative healthcare solutions.
6615.TWO maintains a strong liquidity position, with a current ratio of 3.33, indicating the company can cover its short-term liabilities more than three times over. The company holds TWD 90.6 million in cash and equivalents, which supports its operational flexibility and financial stability. The debt-to-equity ratio is 0.06, suggesting a conservative capital structure with minimal reliance on debt financing.
The company's profitability metrics are currently negative, with a return on equity of -1.49% and a return on assets of -1.29%. These figures indicate that the company is not generating returns that exceed its cost of capital, which is a concern for investors. The operating loss of TWD 33.7 million and a net loss of TWD 9.4 million further highlight the company's current financial challenges.
6615.TWO's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risks if its primary market or product line experiences a downturn.
The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. However, the operating cash flow of TWD 15.4 million and free cash flow of TWD 18.1 million suggest some capacity for reinvestment or debt reduction. The capital expenditure of TWD -8.2 million indicates that the company is not currently investing heavily in new assets.
The risk assessment for 6615.TWO indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is also low, and no adjustments have been applied to its valuation metrics. This suggests that the company is not currently facing significant financial pressures that would necessitate equity dilution.
Recent events and filings for 6615.TWO do not indicate any major changes or developments that would significantly impact its financial position or strategic direction. The company's financial statements and disclosures are consistent with a stable but non-expanding business model.
- 6615.TWO has a strong liquidity position with a current ratio of 3.33 and TWD 90.6 million in cash and equivalents.
- The company is currently unprofitable, with a return on equity of -1.49% and a return on assets of -1.29%.
- 6615.TWO's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company has low liquidity and dilution risks, with no immediate filing-based flags detected.
- 6615.TWO's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 6615.TWO Market data — financials · 2026-05-27